Basically it means that they will sell at the market price.
Nasdaq Companies that go sub $1 and receive notice can often go on runs like was seen at ITUS.
It is very hard to know when/if they will, but as you can see they usually have decent pops.
I usually play them the second plus days for 20%+ gains.
Sadly, not all sustain the first pops over $1 but what can happen is that someone puts in a phantom bid of sorts.
That usually squeezes some shorts who cover.
Last year there was a fantastic trade in SINO in which you could have bought $1.10s and sold for close $2 - which was an early catalyst that allowed the stock to go to $14 in November.
I also traded the move to over $14, but sold most in the $6 area ....
When you have a close to 500% gain, it's easy to dream up things like a house (lol) but I have been in plays that ran up and got snapped off by financings.
Better to take some off the table in chunks so you don't have regrets.
Yeah sure it would have been nice to sell all above $10, but I would have been kicking myself if I let it drift to break-even.
Recent ANIX News
- Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Ovarian Cancer Research Alliance's International Gynecologic Cancer Conference • PR Newswire (US) • 09/18/2024 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 09/06/2024 09:00:27 PM
- Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Rivkin Center-AACR 15th Biennial Ovarian Cancer Research Symposium • PR Newswire (US) • 09/03/2024 12:30:00 PM
- Anixa Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference • PR Newswire (US) • 08/26/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 04:42:57 PM
- Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Clinical Trial at the International Gynecologic Cancer Society 2024 Annual Meeting • PR Newswire (US) • 07/29/2024 12:45:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/29/2024 10:05:44 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/26/2024 05:26:12 PM
- Anixa Biosciences Announces FDA Approval of Individual Patient IND for its Ovarian Cancer CAR-T Therapy • PR Newswire (US) • 07/23/2024 12:15:00 PM
- Anixa Biosciences Announces Japanese Patent on Breast Cancer Vaccine Technology • PR Newswire (US) • 07/17/2024 12:00:00 PM
- Anixa Biosciences Announces $5 Million Share Repurchase Program • PR Newswire (US) • 07/15/2024 12:30:00 PM
- Anixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical Trial • PR Newswire (US) • 06/24/2024 12:45:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 01:22:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 01:56:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 03:18:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/10/2024 02:03:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 04:24:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 02:57:50 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 06/04/2024 09:00:57 PM
- Anixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial • PR Newswire (US) • 05/21/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 12:35:37 PM
- Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer Vaccines • PR Newswire (US) • 05/08/2024 12:25:00 PM
- Anixa Biosciences CEO Featured on "Target: Cancer Podcast" by Oncologist Dr. Sanjay Juneja • PR Newswire (US) • 05/06/2024 12:05:00 PM
- Anixa Biosciences to Participate in the Sidoti Micro-Cap Virtual Conference on May 8 & 9, 2024 • PR Newswire (US) • 04/30/2024 11:45:00 AM
- Anixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay Juneja to its Cancer Business Advisory Board • PR Newswire (US) • 04/18/2024 12:20:00 PM
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM